Cerebrovasculoprotective effects of azilsartan medoxomil in diabetes
- 1 November 2014
- journal article
- Published by Elsevier in Translational Research
- Vol. 164 (5) , 424-432
Abstract
No abstract availableKeywords
Funding Information
- VA Merit Award (BX000347)
- VA Research Career Scientists Award
- National Institutes of Health (R01NS083559)
- Takeda Pharmaceuticals
- USA, Inc
This publication has 39 references indexed in Scilit:
- Effects of suboptimal doses of the AT1 receptor blocker, telmisartan, with the angiotensin-converting enzyme inhibitor, ramipril, on cerebral arterioles in spontaneously hypertensive ratJournal Of Hypertension, 2010
- Renin–Angiotensin System Blockade and Cardiovascular and Renal ProtectionThe American Journal of Cardiology, 2010
- Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programsJournal Of Hypertension, 2009
- Telmisartan to Prevent Recurrent Stroke and Cardiovascular EventsNew England Journal of Medicine, 2008
- Spironolactone improves structure and increases tone in the cerebral vasculature of male spontaneously hypertensive stroke-prone ratsMicrovascular Research, 2007
- Influence of Hyperglycemia on Oxidative Stress and Matrix Metalloproteinase-9 Activation After Focal Cerebral Ischemia/Reperfusion in RatsStroke, 2007
- Vascular Dysfunction of Venous Bypass Conduits Is Mediated by Reactive Oxygen Species in Diabetes: Role of Endothelin-1The Journal of Pharmacology and Experimental Therapeutics, 2005
- Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialThe Lancet, 2004
- Reperfusion Decreases Myogenic Reactivity and Alters Middle Cerebral Artery Function After Focal Cerebral Ischemia in RatsStroke, 1997
- Production of Spontaneous Diabetic Rats by Repetition of Selective BreedingThe Tohoku Journal of Experimental Medicine, 1976